Petroleo Brasileiro SA Petrobras
PBR
Vale SA
VALE
NVIDIA
NVDA
Ecopetrol
EC
Taylor Morrison Home
TMHC
US Stock MarketDetailed Quotes
CGEN Compugen
- 1.5300
- +0.0100+0.66%
Close Mar 28 16:00 ET
- 1.5400
- +0.0100+0.65%
Post 18:54 ET
143.07MMarket Cap-9.56P/E (TTM)
1.5400High1.5200Low136.43KVolume1.5200Open1.5200Pre Close208.37KTurnover0.15%Turnover RatioLossP/E (Static)93.51MShares2.660052wk High2.61P/B140.15MFloat Cap1.350052wk Low--Dividend TTM91.60MShs Float19.9000Historical High--Div YieldTTM1.32%Amplitude0.3400Historical Low1.5270Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Compugen Stock Forum
How Compugen's AI Platform Partnership Could Revolutionize Cancer Immunotherapy Discovery
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology
NEWS PROVIDED BY
Compugen Ltd.
Feb 26, 2025, 07:00 ET
Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing platform to better understand tumor biology and immune regulation
Leveraging Compugen's computational analytical tools un...
Major Breakthrough: AstraZeneca's New Weapon Against Early-Stage Lung Cancer Enters Final Testing
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
Wednesday, 8th January at 7:00 am
• New approach to harness cytokine biology to treat cancer patients advances to the clinic
• First patient dosed with potential first-in-class anti-IL-18 binding protein antibody, COM503, licensed to Gilead Sciences, Inc.
• Phase 1 dose escalation and dose expansion trial...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment.
The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduc...
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
No comment yet